Breaking News Instant updates and real-time market news.

CRBP

Corbus Pharmaceuticals

$6.86 /

-0.32 (-4.46%)

08:38
07/29/20
07/29
08:38
07/29/20
08:38

Corbus Pharmaceuticals announces $121M in new capital

Corbus Pharmaceuticals announced it has received an aggregate of $71M in gross proceeds from its at-the-market offering coupled with the execution of a $50M debt financing facility with K2 HealthVentures. Pursuant to the previously disclosed $75M ATM facility, Corbus has sold 9,167,080 shares at a weighted average price of $7.70 per share. Jefferies, LLC is serving as sales agent for the ATM offering. On July 28, 2020, Corbus entered a debt financing facility with K2HV pursuant to which K2HV agreed to provide up to $50M to Corbus. Corbus received the first $20M tranche upon signing the debt financing agreement and has the option to draw $20 million from the second tranche and $10M from the third tranche, in each case upon achievement of certain regulatory and developmental milestones. K2HV is an alternative investment firm that partners with innovative life sciences and healthcare companies whose success will positively impact and improve outcomes for patients. Morgan Stanley & Co. LLC acted as sole placement agent for the debt financing. The Company expects its cash and cash equivalents on hand of approximately $101M at July 28, 2020 to fund operations into the third quarter of 2021.

  • 07

    Feb

CRBP Corbus Pharmaceuticals
$6.86 /

-0.32 (-4.46%)

07/27/20 Jefferies
Corbus Pharmaceuticals price target raised to $18 from $17 at Jefferies
07/07/20 Roth Capital
Corbus Pharmaceuticals initiated with a Buy at Roth Capital
06/22/20 BTIG
Corbus Pharmaceuticals' Phase 2b CF data readouts seen in Q3, says BTIG
06/16/20 BTIG
Corbus Pharmaceuticals initiated with a Buy at BTIG

TODAY'S FREE FLY STORIES

Upgrade
BofA upgrades First Solar to Buy on higher visibility and confidence » 07:49
08/07/20
08/07
07:49
08/07/20
07:49
FSLR

First Solar

$64.42 /

-1.315 (-2.00%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

07:42 Today BofA
First Solar upgraded to Buy from Neutral at BofA
07:00 Today UBS
First Solar price target raised to $75 from $63 at UBS
06:34 Today Roth Capital
First Solar price target raised to $65 from $56 at Roth Capital
06:27 Today Barclays
First Solar price target lowered to $45 from $51 at Barclays
FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

Hot Stocks
AnPac Bio validating approved COVID-19 antibody test » 07:48
08/07/20
08/07
07:48
08/07/20
07:48
ANPC

AnPac Bio

$5.50 /

-0.3 (-5.17%)

AnPac Bio-Medical Science…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ANPC AnPac Bio
$5.50 /

-0.3 (-5.17%)

ANPC AnPac Bio
$5.50 /

-0.3 (-5.17%)

  • 30
    Jan
Hot Stocks
Sabre sees $275M in cost savings in 2020 » 07:46
08/07/20
08/07
07:46
08/07/20
07:46
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

"Our thoughts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Hot Stocks
Arbutus cannot predict negative impacts from COVID-19 on plans, timelines » 07:46
08/07/20
08/07
07:46
08/07/20
07:46
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

In December 2019 an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Hot Stocks
Arbutus entitled to receive tiered low single digit royalties on Genevant sales » 07:46
08/07/20
08/07
07:46
08/07/20
07:46
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

On July 23, 2020, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Hot Stocks
Sabre not giving guidance at this time » 07:45
08/07/20
08/07
07:45
08/07/20
07:45
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

Given the magnitude and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Recommendations
Uber price target raised to $46 from $44 at Morgan Stanley » 07:45
08/07/20
08/07
07:45
08/07/20
07:45
UBER

Uber

$34.70 /

+1.49 (+4.49%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UBER Uber
$34.70 /

+1.49 (+4.49%)

UBER Uber
$34.70 /

+1.49 (+4.49%)

07:26 Today Wedbush
Uber price target lowered to $41 from $47 at Wedbush
06:42 Today Mizuho
Uber price target raised to $42 from $40 at Mizuho
06:28 Today KeyBanc
Uber's results likely to remain 'inconsistent' in the near-term, says KeyBanc
06:24 Today Barclays
Uber price target raised to $43 from $39 at Barclays
UBER Uber
$34.70 /

+1.49 (+4.49%)

  • 11
    Feb
  • 07
    Nov
  • 06
    Nov
UBER Uber
$34.70 /

+1.49 (+4.49%)

UBER Uber
$34.70 /

+1.49 (+4.49%)

UBER Uber
$34.70 /

+1.49 (+4.49%)

General news
Treasury Market Outlook: nervousness ahead of the jobs report has weighed slightly on equities » 07:45
08/07/20
08/07
07:45
08/07/20
07:45

Treasury Market Outlook:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
Sabre CEO says 'overall travel environment remains severely depressed' » 07:44
08/07/20
08/07
07:44
08/07/20
07:44
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

"This remains an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Hot Stocks
Arbutus Biopharma sees 2020 cash burn $54M-$58M » 07:44
08/07/20
08/07
07:44
08/07/20
07:44
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Earlier this year, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Hot Stocks
Arbutus Biopharma expects to complete IND-enabling studies of AB-836 by year-end » 07:44
08/07/20
08/07
07:44
08/07/20
07:44
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

In January 2020, Arbutus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Recommendations
AMN Healthcare price target raised to $65 from $50 at BMO Capital » 07:43
08/07/20
08/07
07:43
08/07/20
07:43
AMN

AMN Healthcare

$55.22 /

-0.7 (-1.25%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

07/21/20 SunTrust
AMN Healthcare upgraded to Buy from Hold at SunTrust
07/21/20 SunTrust
AMN Healthcare upgraded to Buy from Hold at SunTrust
05/13/20 BMO Capital
AMN Healthcare price target lowered to $50 from $79 at BMO Capital
05/12/20 Credit Suisse
AMN Healthcare price target lowered to $62 from $81 at Credit Suisse
AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

Hot Stocks
Arbutus expects results from cohort in AB-729 trial in 2H20 » 07:43
08/07/20
08/07
07:43
08/07/20
07:43
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Arbutus is dosing two 60…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Earnings
Sabre reports Q2 adjusted EPS ($1.30), consensus (84c) » 07:42
08/07/20
08/07
07:42
08/07/20
07:42
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

Reports Q2 revenue $83M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Upgrade
First Solar upgraded to Buy from Neutral at BofA » 07:42
08/07/20
08/07
07:42
08/07/20
07:42
FSLR

First Solar

$64.42 /

-1.315 (-2.00%)

BofA analyst Julien…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

07:00 Today UBS
First Solar price target raised to $75 from $63 at UBS
06:34 Today Roth Capital
First Solar price target raised to $65 from $56 at Roth Capital
06:27 Today Barclays
First Solar price target lowered to $45 from $51 at Barclays
07/27/20
Fly Intel: Top five analyst downgrades
FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

Hot Stocks
Arbutus Biopharma expects cash to fund operations into mid-2022 » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Arbutus had cash, cash…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Recommendations
PowerFleet price target raised to $8 from $6 at Ladenburg » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
PWFL

PowerFleet

$5.95 /

-0.02 (-0.34%)

Ladenburg Thalmann…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PWFL PowerFleet
$5.95 /

-0.02 (-0.34%)

PWFL PowerFleet
$5.95 /

-0.02 (-0.34%)

05/04/20 B. Riley FBR
PowerFleet downgraded to Neutral, target cut to $4.75 at B. Riley FBR
05/04/20 B. Riley FBR
PowerFleet downgraded to Neutral from Buy at B. Riley FBR
03/30/20 Roth Capital
PowerFleet resumed with a Buy at Roth Capital
10/04/19 Canaccord
PowerFleet contends in fleet management, initiated with a Buy at Canaccord
PWFL PowerFleet
$5.95 /

-0.02 (-0.34%)

Recommendations
Yeti price target raised to $65 from $55 at BTIG » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
YETI

Yeti

$50.81 /

-0.86 (-1.66%)

BTIG analyst Camilo Lyon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
YETI Yeti
$50.81 /

-0.86 (-1.66%)

YETI Yeti
$50.81 /

-0.86 (-1.66%)

06:29 Today KeyBanc
Yeti price target raised to $56 from $38 at KeyBanc
08/04/20 Baird
Baird remains bullish on Yeti Holdings' long-term growth story
07/30/20 BTIG
Yeti price target raised to $55 from $44 at BTIG
07/24/20 Stifel
Yeti price target raised to $45 from $33 at Stifel
YETI Yeti
$50.81 /

-0.86 (-1.66%)

  • 28
    May
  • 11
    May
  • 17
    Feb
  • 07
    Nov
YETI Yeti
$50.81 /

-0.86 (-1.66%)

YETI Yeti
$50.81 /

-0.86 (-1.66%)

Earnings
Arbutus Biopharma reports Q2 EPS (25c), consensus (24c) » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Recommendations
ViacomCBS price target raised to $35 from $24 at Benchmark » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
VIAC

ViacomCBS

$26.88 /

+0.88 (+3.38%)

Benchmark analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

07/13/20
Fly Intel: Top five analyst initiations
07/13/20
Fly Intel: Top five analyst downgrades
07/13/20 Wells Fargo
ViacomCBS price target raised to $19 from $13 at Wells Fargo
07/13/20 BofA
ViacomCBS downgraded to Neutral from Buy at BofA
VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

Recommendations
Celsius Holdings price target raised to $23.50 from $11.75 at Ladenburg » 07:39
08/07/20
08/07
07:39
08/07/20
07:39
CELH

Celsius Holdings

$20.86 /

+5.25 (+33.63%)

Ladenburg analyst Jeffrey…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CELH Celsius Holdings
$20.86 /

+5.25 (+33.63%)

CELH Celsius Holdings
$20.86 /

+5.25 (+33.63%)

08/06/20 Roth Capital
Celsius Holdings price target raised to $25 from $14.50 at Roth Capital
07/28/20 B. Riley FBR
Celsius Holdings price target raised to $17 from $11.50 at B. Riley FBR
06/24/20 Maxim
Celsius Holdings price target raised to $15 from $12 at Maxim
04/30/20 Roth Capital
Celsius Holdings initiated with a Buy at Roth Capital
CELH Celsius Holdings
$20.86 /

+5.25 (+33.63%)

  • 12
    Sep
Earnings
PFSweb sees 2020 consolidated SFE revenue growth 9%-12% » 07:39
08/07/20
08/07
07:39
08/07/20
07:39
PFSW

PFSweb

$9.58 /

-0.065 (-0.67%)

Revenue consensus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

08/03/20 B. Riley FBR
PFSweb price target raised to $9.50 from $7.50 at B. Riley FBR
05/08/20 Lake Street
PFSweb set to benefit from more direct to consumer sales, says Lake Street
01/06/20 Craig-Hallum
PFSweb upgraded to Buy from Hold at Craig-Hallum
11/12/19 Lake Street
Lake Street upgrades PFSweb to Buy, ups target to $5 from $4
PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

Recommendations
Papa John's price target raised to $115 from $95 at BTIG » 07:38
08/07/20
08/07
07:38
08/07/20
07:38
PZZA

Papa John's

$97.38 /

-1.945 (-1.96%)

BTIG analyst Peter Saleh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

06:45 Today Credit Suisse
Papa John's price target raised to $110 from $90 at Credit Suisse
07/27/20 Stephens
McDonald's, Domino's among restaurant stocks to own now, says Stephens
07/27/20 Longbow
Papa John's U.S. comps up high-teens percentage in recent weeks, says Longbow
07/01/20
Fly Intel: Top five analyst initiations
PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

Recommendations
BeiGene price target raised to $268 from $232 at Ladenburg » 07:38
08/07/20
08/07
07:38
08/07/20
07:38
BGNE

BeiGene

$224.41 /

-1.59 (-0.70%)

Ladenburg analyst Wangzhi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BGNE BeiGene
$224.41 /

-1.59 (-0.70%)

BGNE BeiGene
$224.41 /

-1.59 (-0.70%)

08/06/20 Piper Sandler
BeiGene price target raised to $175 from $165 at Piper Sandler
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
07/13/20 Maxim
BeiGene price target raised to $250 from $190 at Maxim
BGNE BeiGene
$224.41 /

-1.59 (-0.70%)

BGNE BeiGene
$224.41 /

-1.59 (-0.70%)

Earnings
PFSweb reports Q2 EPS (5c), consensus 0c » 07:38
08/07/20
08/07
07:38
08/07/20
07:38
PFSW

PFSweb

$9.58 /

-0.065 (-0.67%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

08/03/20 B. Riley FBR
PFSweb price target raised to $9.50 from $7.50 at B. Riley FBR
05/08/20 Lake Street
PFSweb set to benefit from more direct to consumer sales, says Lake Street
01/06/20 Craig-Hallum
PFSweb upgraded to Buy from Hold at Craig-Hallum
11/12/19 Lake Street
Lake Street upgrades PFSweb to Buy, ups target to $5 from $4
PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.